Short Interest in Firefly Neuroscience, Inc. (NASDAQ:AIFF) Expands By 300.2%

Firefly Neuroscience, Inc. (NASDAQ:AIFF) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 1,551,962 shares, a growth of 300.2% from the February 26th total of 387,780 shares. Based on an average daily volume of 45,958,225 shares, the short-interest ratio is presently 0.0 days. Currently, 11.7% of the company’s stock are sold short. Currently, 11.7% of the company’s stock are sold short. Based on an average daily volume of 45,958,225 shares, the short-interest ratio is presently 0.0 days.

Firefly Neuroscience Price Performance

Shares of AIFF stock opened at $1.82 on Wednesday. Firefly Neuroscience has a 1-year low of $0.62 and a 1-year high of $4.77. The stock’s 50-day moving average is $1.16 and its 200 day moving average is $1.67. The company has a market cap of $25.88 million, a P/E ratio of -0.87 and a beta of 1.92.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of Firefly Neuroscience

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Firefly Neuroscience in the 4th quarter worth approximately $53,000. Vanguard Group Inc. lifted its position in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after acquiring an additional 401,085 shares during the last quarter. Savvy Advisors Inc. purchased a new stake in Firefly Neuroscience during the third quarter valued at approximately $63,000. Finally, Geode Capital Management LLC boosted its stake in Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after acquiring an additional 58,067 shares in the last quarter. 4.96% of the stock is currently owned by institutional investors.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.